Company / Return on Equity (ROE)
Valion Bio, Inc. Return on Equity (ROE) History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-230.3%
FY2024
5-year range
-278.1% / -64.0%
FY2022-FY2024
Trend
+17.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Valion Bio, Inc. reports negative total equity of -230.3% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-230.3% in FY2024.
Declined from -64.0% to -230.3% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 17.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -230.3% | +17.2% |
| FY2023 | -278.1% | -334.6% |
| FY2022 | -64.0% | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026